Hello and Welcome to Patientsville.com, Your Source for all MESNA information. We are dedicated to provide You with MESNA safety information. Learn about MESNA serious adverse events reported to Food and Drug Administration (FDA).
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
MESNA Safety Reports
Total MESNA reports: 2.MESNA FDA safety alerts: No.
Reported hospitalizations: 1.
Take MESNA Side Effects Survey or Share Your MESNA Story. Read More Here.
Physician from UNITED STATES reported MESNA problem on Sept 10, 2007. Female patient, 21 years of age, was diagnosed with burkitt's lymphoma, tumour lysis syndrome, prophylaxis of nausea and vomiting and was treated with MESNA. After drug was administered, patient experienced the following problems/side effects: asthenia, b-cell lymphoma, back pain, caesarean section, diarrhoea, fatigue, febrile neutropenia, fibrosis. MESNA dosage: 360 MG/M2 (360 MG/M2, 1-5 DAYS) INTRAVENOUS (NOT OTHERWISE SPECIFIED). During the same period patient was treated with IFOSFAMIDE, DOXORUBICIN, CYTARABINE, ETOPOSIDE, ALLOPURINOL, ONDANSETRON, DEXAMETHASONE. Patient recovered.
MESNA problem was reported by a Physician from UNITED STATES on Sept 10, 2007. Male patient was diagnosed with burkitt's lymphoma and was treated with MESNA. After drug was administered, patient experienced the following problems/side effects: caesarean section, clostridium difficile colitis, congenital pneumonia, cyanosis neonatal, febrile neutropenia, neonatal respiratory distress syndrome, platelet count increased, premature baby. MESNA dosage: 360 MG/M2 (360 MG/M2, 1 IN 1 D) TRANSPLACENTAL. During the same period patient was treated with IFOSFAMIDE, DOXORUBICIN, CYTARABINE, ETOPOSIDE, ALLOPURINOL, ONDANSETRON, METHOTREXATE, DEXAMETHASONE. Patient was hospitalized. Patient recovered.